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Clinical development of new anticancer drugs can be compromised by a lack of qualified biomarkers. An indispensable component to
successful biomarker qualification is assay validation, which is also a regulatory requirement. In order to foster flexible yet rigorous
biomarker method validation, the fit-for-purpose approach has recently been developed. This minireview focuses on many of the
basic issues surrounding validation of biomarker assays utilised in clinical trials. It also provides an overview on strategies to validate
each of the five categories that define the majority of biomarker assays.
British Journal of Cancer (2010) 103, 1313–1317. doi:10.1038/sj.bjc.6605910 www.bjcancer.com
Published online 5 October 2010
& 2010 Cancer Research UK
Keywords: biomarkers; validation; clinical trials; fit-for-purpose
                                        
During anticancer drug development, biomarkers can have many
applications. They may be utilised as discovery tools, as
pharmacodynamic (PD) markers of drug mechanism or efficacy
both preclinically and in early phase trials, and as predictive
indices of patient response in late phase trials (Lee et al, 2005;
Sarker and Workman, 2007). Thus, incorporation of biomarkers
into clinical trials has the potential to guide and accelerate the pace
of development of new anticancer drugs (McShane et al, 2009).
Biomarkers may also provide a diagnostic readout on tumour
biology in experimental cancer medicine or be prognostic or
predictive of disease or therapeutic outcome (Ludwig and
Weinstein, 2005). However, at present there are few fully qualified
biomarkers available to utilise in clinical trials of anticancer drugs
(Jain et al, 2009). Assay characterisation remains a critical
component in biomarker qualification and often biomarkers can
fail not because of the underlying science, but because of poor
choice of assay and lack of validation (Carden et al, 2010).
The UK clinical trials regulations state that ‘systems with
procedures that assure the quality of every aspect of the trial
should be implemented’, which includes method validation
(Cummings et al, 2008). Although there is now a raft of regulatory
guidance documents associated with clinical trials these make few
references to method validation and there is a need for
amplification on many of the issues associated with biomarker
analysis (Cummings et al, 2008). Recently the ‘fit-for-purpose’
approach has emerged to provide guidance on biomarker method
validation (Lee et al, 2005, 2006; Tan et al, 2009). The present
commentary seeks to clarify and extend this approach.
FIT-FOR-PURPOSE BIOMARKER METHOD
VALIDATION
The benchmark definition of method validation has been
presented by the International Organisation for Standardisation
as ‘the confirmation by examination and the provision of objective
evidence that the particular requirements for a specific intended
use are fulfilled’. Although this definition appears self evident, its
full implications are often overlooked (Feinberg et al, 2004;
Boulanger et al, 2009). Thus, ideally validation should progress
down two parallel tracks which eventually converge—one experi-
mental, the other operational. The first is to establish the purpose
of the method and agree upon outcomes, target values or
acceptance limits, whereas the second is to characterise the
performance of the assay by experimentation. The critical step in
the whole process then rests on the evaluation of technical
performance against the predefined purpose. If the assay can
deliver to expectations, then it is deemed fit for that purpose. If
not, then it cannot be considered fit for the specified purpose.
Comparing performance specifications against predefined accep-
tance limits in isolation of purpose does not conform to the strict
definition of method validation. Nevertheless, technical data can
have an important role in verifying that the assay is working
properly and in aiding in the diagnosis of faults (Rozet et al, 2007).
The position of the biomarker in the spectrum between research
tool and clinical end point dictates the stringency of experimental
proof required to achieve method validation (Lee et al, 2007). In
addition, the nature of the analytical technology also influences the
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www.bjcancer.comlevel of performance verification required (Figure 1). The
availability of novel technology platforms such as the omics
technologies allow more scientific questions to be posed, but
represent additional analytical challenges in terms of assay
validation. In many cases, these technologies will provide a set
of biomarker candidates that need to be verified by a more robust
and conventional analytical method.
HOW TO CONDUCT FIT-FOR-PURPOSE BIOMARKER
METHOD VALIDATION?
The American Association of Pharmaceutical Scientists (AAPS)
and the US Clinical Ligand Society have identified five general
classes of biomarker assays (Lee et al, 2005). A definitive
quantitative assay makes use of calibrators and a regression model
to calculate absolute quantitative values for unknowns. The
reference standard is fully characterised and representative of
the biomarker. A relative quantitative assay uses a response–
concentration calibration with reference standards that are not
fully representative of the biomarker. A quasi-quantitative assay
does not employ a calibration standard, but has a continuous
response that can be expressed in terms of a characteristic of
the test sample. Qualitative (categorical) assays can either be
described as ordinal reliant on discrete scoring scales like those
used in immunohistochemistry (IHC) or nominal that pertains to a
yes/no situation; for example, the presence or absence of a gene
product (Lee et al, 2005, 2006, 2007). Table 1 represents the
consensus position on which parameters should be investigated for
each class of biomarker assay.
THE DIFFERENT PHASES OF FIT-FOR-PURPOSE
BIOMARKER ASSAY VALIDATION
Biomarker method validation can be envisaged as proceeding
through discrete stages (Shah et al, 2000; Lee et al, 2005, 2006). The
first stage is where definition of purpose and selection of the
candidate assay occurs, and is perhaps the most critical. During
stage 2 the goal is to assemble all the appropriate reagents and
components, write the method validation plan and decide upon the
final classification of the assay. Stage 3 is the experimental phase of
performance verification leading to the all important evaluation of
fitness-for-purpose culminating in writing a standard operating
procedure. In-study validation (stage 4) allows further assessment
of fitness-of-purpose and the robustness of the assay in the clinical
context and enables identification of patient sampling issues, such
as collection, storage and stability. Stage 5 is where the assay enters
routine use, and here, quality control (QC) monitoring, proficiency
testing and batch-to-batch QC issues can be fully explored. The
driver of the process is one of continual improvement, which may
necessitate a series of iterations that can lead back to any one of
the earlier stages (Lee et al, 2006, 2007).
VALIDATION OF DEFINITIVE QUANTITATIVE
BIOMARKER ASSAYS
Examples of definitive quantitative biomarker methods include
mass spectrometric analysis. The objective of a definitive
quantitative method is to determine as accurately as possible the
unknown concentrations of the biomarker in the patient samples
under investigation (Rozet et al, 2007). Analytical accuracy is
dependant on the total error in the method, consisting of the sum
of the systematic error component (bias) and the random error
component (intermediate precision; DeSilva et al, 2003). Total
error takes account of all relevant sources of variation: for
example, day, analyst, analytical platform or batch (Cummings
et al, 2008).
Recognised performance standards have been established for
bioanalysis of small molecules by the pharmaceutical industry
(Shah et al, 1991, 2000). An evaluation of both precision
(% coefficient of variation (CV)) and accuracy (mean % deviation
from nominal concentration) is required. Repeat analyses of the
pre-study validation samples (VS) are expected to vary by o15%,
except at the lower limit of quantitation (LLOQ) where 20% is
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Figure 1 Overview of fit-for-purpose biomarker method validation. The
fit-for-purpose approach to biomarker method validation tailors the burden
of proof required to validate an assay to take account of both the nature of
technology utilised and position of the biomarker in the spectrum between
research tool and clinical end point. Ultimately, fit-for-purpose requires
an assessment of the technical ability of the assay to deliver against
the predefined purpose. Abbreviations: IHC¼immunohistochemistry;
LBA¼ligand binding assay; MS¼mass spectrometry; PD¼pharmaco-
dynamic; POM¼proof of mechanism; POC¼proof of concept.
Table 1 Recommended performance parameters that should be evaluated during biomarker method validation based on assay technology category
Performance characteristic Definitive quantitative Relative quantitative Quasi-quantitative Qualitative
Accuracy +
Trueness (bias) + +
Precision + + +
Reproducibility +
Sensitivity + + + +
LLOQ LLOQ
Specificity + + + +
Dilution linearity + +
Parallelism + +
Assay range + + +
LLOQ–ULOQ LLOQ–ULOQ
Abbreviations: LLOQ¼lower limit of quantitation; ULOQ¼upper limit of quantitation.
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control samples (QCs) should be employed at three different
concentrations spanning the calibration curve. A run is accepted as
valid when at least 67% (4/6) of the QCs fall within 15% of their
nominal values (the 4:6:15 rule; Shah et al, 1991, 2000).
More flexibility is allowed in biomarker method validation
where during pre-study validation each assay can be evaluated on a
case per case basis, with 25% being the default value (30% at the
LLOQ) for precision and accuracy. A similar approach may be
adopted during patient sample analysis in setting acceptance limits
for QCs, either in terms of a 4:6:X rule or through adoption of
confidence intervals (Lee et al, 2005, 2006, 2007). On a note of
caution, applying fixed performance criteria in the absence of
statistical evaluation that they are relevant to the assay under
investigation has been challenged (Findlay, 2008, 2009). Adopting
a 4:6:X rule of acceptability for the QCs could mean at best that
33% of the patient samples will also not fall within the acceptance
limits. Researchers have seriously questioned whether a method
can be considered fit-for-purpose on the basis of a 4:6:X rule
(Boulanger et al, 2009). The Societe Francaise des Sciences et
Techniques Pharmaceutiques (SFSTP) has published a series of
papers on fit-for-purpose validation of quantitative analytical
techniques based on an ‘accuracy profile’ (Boulanger et al, 2003;
Feinberg et al, 2004). The accuracy profile takes account of total
error (bias and intermediate precision), a pre-set acceptance limit
that the user defines and produces a plot based on the
‘b-expectation tolerance interval’ that displays the confidence
interval (e.g. 95%) for future measurements. Effectively, the
accuracy profile allows researchers to visually check what
percentage of future values are likely to fall with the pre-defined
acceptance limit. To construct an accuracy profile the SFSTP
recommend that 3–5 different concentrations of calibration
standards and 3 different concentrations of VS (representing high,
medium and low points on the calibration curve) are run in
triplicate on 3 separate days, (Feinberg et al, 2004; Feinberg, 2007;
Rozet et al, 2007). Biomarkers methods may require a greater
number of calibration standards and VS due to nonlinearity.
Other performance parameters such as sensitivity, dynamic
range, LLOQ and upper limit of quantitation (ULOQ) can be
obtained from the accuracy profile. As with all five categories of
biomarker assays sample and reagent integrity should also be
carefully assessed during method validation, including studies on
sample stability during collection, storage and analysis (Nowatzke
and Wood, 2007). Studies on specificity, dilution linearity and
parallelism with a definitive quantitative biomarker are essential, but
are perhaps less problematic than with a relative quantitative assay
(see below), as the VS are by their nature more similar in com-
position to patient samples and should behave in a similar manner.
VALIDATION OF RELATIVE QUANTITATIVE
BIOMARKER ASSAYS
The ligand binding assay (LBA) is the archetypical quantitative
assay for endogenous (protein) macromolecular biomarkers.
However, as most biomarker LBA ligands are endogenous
substances and already present in patient/volunteer samples, an
analyte-free matrix to utilise during validation studies is more
difficult to obtain. Access to a fully characterised form of
biomarker to act as a calibration standard is also limited. Thus,
most available biomarker LBA fall into the category of relative
quantitation (Lee et al, 2005).
Ligand binding assay is associated with a multiplicity of
specificity issues (Findlay, 2008). Biotransformation caused by a
variety of factors can introduce new forms of the biomarker into
samples with ill-defined behaviour in the ELISA assay (Mahler
et al, 2009). Complexation of the ligand with a soluble receptor,
protein aggregation, folding/unfolding of the ligand can mask or
reveal antibody epitope binding sites (Cummings et al, 2007).
Ligand binding assay are also dependant on the integrity of
reagents such as antibodies, which are subject to their own issues
of supply and stability. Concentrations of the biomarker in the
disease group of interest are often unknown, and thus, target
expectations are more difficult to define in advance. Ligand
binding assay are also susceptible to sample non-dilution linearity
and interference with heterophilic antibodies can result in false
positive results (Findlay, 2009).
Only precision and bias can be evaluated during pre-study
validation, not accuracy. Nonetheless, depending on the nature of
the calibration standards and matrix of choice, precision and bias
determined in VS and QCs may reflect only poorly the true
analytical behaviour of the assay with patient samples. As the
calibration curve for most LBA are non-linear, the AAPS
recommend that at least 8–10 different non-zero concentration
should be run on 3–6 separate occasions to establish the most
appropriate calibration model (DeSilva et al, 2003). Careful
attention should be paid to the curve fitting routine such as 4 or
5-PL and to weighting, and the working effective range of the assay
should be based on the precision profile where the deviation from
the line of best fit for back calculated values should lie within an
acceptance limit of 10–20% (Kelley and DeSilva, 2007). During
pre-study validation, at least five different concentrations of VS
spanning the calibration curve—including LLOQ; 3  LLOQ, mid-
range, high and ULOQ—should be analysed in duplicate on at least
six different runs. Inter-batch precision and bias should be
o±20% for each parameter, except at the LLOQ and the ULOQ
where ±25% is acceptable (Viswanathan et al, 2007). Similar
acceptance limits were recommended for in-study validation with
QCs, but here only three different concentrations were required to
be run in duplicate and a 4:6:X rule utilised. These recommenda-
tions have been largely adopted in biomarker method validation,
but with allowances to extend acceptance criteria if scientifically
justified (Lee et al, 2005, 2006, 2007). However, we believe that it is
preferable that acceptance criteria should be based on total error
coupled to a confidence interval of 95%, especially with the higher
degree of uncertainty associated with relative quantitative methods
(Lee et al, 2005, 2006, 2007). For reasons stated above, the 4:6:X
rule should be avoided.
Specificity is defined as the ability to measure the analyte of
interest in the presence of other components in the assay matrix.
There are two types of non-specificities: specific non-specificity
and non-specific non-specificity (Kelley and DeSilva, 2007).
Specific non-specificity can result in interference from macro-
molecules structurally related to or derived from the biomarker.
Non-specific non-specificity (matrix effect) can result in inter-
ference from unrelated species and matrix components, but can
often be eliminated by dilution of sample in an appropriate buffer.
To prove specificity, the AAPS requires evaluation of the
concentration–response relationships of both spiked and non-
spiked samples obtained from 6–10 different patient derived
sources.
Recently, incurred (patient) sample reanalysis (ISR) has been
strongly recommended in bioanalysis as a more rigorous test of
assay reproducibility, rather than the use of QCs (Fast et al, 2009).
Such an approach has even greater relevance in all five categories
of biomarker assays and especially in situations where QCs are
usually less representative of clinical samples, such as in the case of
relative quantitative techniques (Findlay, 2009).
The study of dilution linearity and especially parallelism in
performance verification of relative quantitative assays such as
LBA cannot be over emphasised. Dilution linearity is normally
studied with spiked QCs during pre-study method validation and
care has to be exercised in the choice of matrix to act as the diluent
(Greystoke et al, 2008). Whereas, parallelism is assessed using
multiple dilutions of study samples that fall on the quantitative
range of the calibration curve and can be conducted on either
Biomarker method validation
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(Kelley and DeSilva, 2007). There are two ways of representing
parallelism: the first is as a plot of measured concentrations for the
patient samples against 1/dilution factor using log scales. A linear
regression analysis is performed and acceptance criteria can be
based either on correlation coefficients or a statistical acceptance
criterion of o20% for the deviation of each dilution from the
line of best fit (Findlay et al, 2000). Alternatively, a plot of
measured concentrations for the patient samples x dilution factor
against 1/dilution can be constructed. This should yield a flat
line so that the CV among the recovered concentrations
at different dilutions can be used to verify parallelism and here a
CV of o30% is reported as the acceptance limit (Kelley and
DeSilva, 2007).
VALIDATION OF QUASI-QUANTITATIVE
BIOMARKER ASSAYS
This category of biomarker assay lacks calibration against a
certified standard, but reports numerical values as a characteristic
of the sample. Examples of such assays include quantitative
RT–PCR. Performance parameters that form the core of pre-study
validation include precision, specificity, sensitivity and the
dynamic range of the assay.
To illustrate the principles of fit-for-purpose validation of a
quasi-quantitative assay an ELISA measuring DNA nucleosomes
(nDNA) as a biomarker of cell death (Cell Death Detection
ELISA
Plus from ROCHE Diagnostics, Ltd., Burgess Hill, UK) is
chosen as a typical example. This particular sandwich ELISA is
only supplied with a positive control and is not calibrated against a
standard, so assay readout is in absorbance units generated by the
microplate reader. In addition, QCs are prepared with the positive
control, but are of limited value, as they are reconstituted in buffer.
The fit-for-purpose approach adopted therefore focused on
demonstrating utility in the analysis of clinical trial samples.
Stability studies focussed on nDNA spiked into serum or plasma to
replicate patient samples. Careful handling of whole blood was
critical in avoiding haemolysis, while isolation of serum or plasma
was essential as soon as practicable in order to store samples at
 801C, before analysis. A protocol was developed for assay
validation during in study analysis of patient samples that included
4–6 replicates of the positive control QC to verify assay
performance and up to 6 patient samples for ISR, as the primary
test of QC and reproducibility. Application of the assay to the
analysis of clinical specimens confirmed clinical utility both as a
PD marker (Dean et al, 2009) and as a predictive biomarker of
response to cancer chemotherapy (Hou et al, 2009). Paradoxically,
biomarker assays such as quasi-quantitative or qualitative
techniques that require verification of fewer performance char-
acteristics, have perhaps an even greater requirement to be fast
tracked into the clinic in order to complete or even initiate the
process of validation.
VALIDATION OF QUALITATIVE BIOMARKER ASSAYS
Often positioned at the diagnostic end of the biomarker spectrum,
examples of qualitative biomarker assays include western blotting,
IHC and fluorescence in situ hybridisation. Positive and negative
controls are the mainstay to confirm assay performance (Lee et al,
2005, 2006). Proving analytical and more importantly clinical
specificity and sensitivity is the key to validation of this category of
biomarker assay, but such a process can require access to
resources which are not readily available, such as knock out mice,
cell lines with overexpression of the target protein or clinical
specimens. Under these circumstances, a risk-based approach to
proving specificity is recommended, where more limited studies
are conducted with resources that are more readily available.
The Clinical Laboratory Standards Institute (CLSI) evaluation
protocol for a qualitative diagnostic test recommends analysis of a
minimum of 50 positive and 50 negative specimens run over
10–20 days, in the absence of an existing body of validation data.
If, however, a body of validation can be provided by the vendor or
supplier, then more limited studies to confirm performance within
manufacturer’s specifications should be adequate.
In conclusion, the realisation that patients have consented in
good faith to donate samples for clinical research mandates the
scientific community to ensure that experimental design is
appropriate and that the assays employed are validated. Fit-
for-purpose validation provides biomarker researchers with an
approach that tailors the burden and stringency of proof required
to validate an assay to take account of both the nature
of technology utilised and the context in which the biomarker
will be applied.
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